Agomelatine is an innovative antidepressant that acts as a melatonergic agonist at MT₁ and MT₂ receptors and a serotonin 5-HT₂C antagonist, helping to regulate circadian rhythms, improve sleep, and elevate mood. Developed in the 1990s by Servier and approved in Europe in 2009, it offers antidepressant effects with minimal side effects like sexual dysfunction or weight gain. By combining chronobiotic properties with traditional mood regulation, agomelatine provides a novel approach for treating major depressive disorder, especially in patients with disrupted sleep-wake cycles.
Image
